Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(4), 916-939; doi:10.3390/ph3040916
Review

Combating Combination of Hypertension and Diabetes in Different Rat Models

* ,
 and
Received: 5 January 2010; in revised form: 4 March 2010 / Accepted: 18 March 2010 / Published: 26 March 2010
(This article belongs to the Special Issue Antihypertensive Drugs)
View Full-Text   |   Download PDF [206 KB, uploaded 26 March 2010]
Abstract: Rat experimental models are used extensively for studying physiological mechanisms and treatments of hypertension and diabetes co-existence. Each one of these conditions is a major risk factor for cardiovascular disease (CVD), and the combination of the two conditions is a potent enhancer of CVD. Five major animal models that advanced our understanding of the mechanisms and therapeutic approaches in humans are discussed in this review: Zucker, Goto-Kakizaki, SHROB, SHR/NDmcr-cp and Cohen Rosenthal diabetic hypertensive (CRDH) rats. The use of various drugs, such as angiotensin-converting enzyme (ACE) inhibitors (ACEIs), various angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs), to combat the effects of concomitant pathologies on the combination of diabetes and hypertension, as well as the non-pharmacological approach are reviewed in detail for each rat model. Results from experiments on these models indicate that classical factors contributing to the pathology of hypertension and diabetes combination—Including hypertension, hyperglycemia, hyperinsulinemia and hyperlipidemia—can now be treated, although these treatments do not completely prevent renal complications. Animal studies have focused on several mechanisms involved in hypertension/diabetes that remain to be translated into clinical medicine, including hypoxia, oxidative stress, and advanced glycation. Several target molecules have been identified that need to be incorporated into a treatment modality. The challenge continues to be the identification and interpretation of the clinical evidence from the animal models and their application to human treatment.
Keywords: hypertensive-diabetic animal models – treatment; Zucker rats; Goto-Kakizaki rats; SHROB rats; SHR/NDmcr-cp rats; Cohen Rosenthal diabetic hypertensive rats hypertensive-diabetic animal models – treatment; Zucker rats; Goto-Kakizaki rats; SHROB rats; SHR/NDmcr-cp rats; Cohen Rosenthal diabetic hypertensive rats
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Rosenthal, T.; Younis, F.; Alter, A. Combating Combination of Hypertension and Diabetes in Different Rat Models. Pharmaceuticals 2010, 3, 916-939.

AMA Style

Rosenthal T, Younis F, Alter A. Combating Combination of Hypertension and Diabetes in Different Rat Models. Pharmaceuticals. 2010; 3(4):916-939.

Chicago/Turabian Style

Rosenthal, Talma; Younis, Firas; Alter, Ariela. 2010. "Combating Combination of Hypertension and Diabetes in Different Rat Models." Pharmaceuticals 3, no. 4: 916-939.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert